US5663180A
(en)
*
|
1983-10-29 |
1997-09-02 |
G.D. Searle & Co. |
Substituted cyclopentenes for the treatment of inflammation
|
EP0759432A1
(en)
*
|
1993-01-15 |
1997-02-26 |
G.D. Searle & Co. |
Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a skin-related condition
|
US6492413B2
(en)
|
1993-01-15 |
2002-12-10 |
G.D. Searle & Co. |
3.4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
|
GB9420616D0
(en)
*
|
1994-10-12 |
1994-11-30 |
Merck Sharp & Dohme |
Method, compositions and use
|
US6090834A
(en)
*
|
1993-05-21 |
2000-07-18 |
G.D. Searle & Co. |
Substituted oxazoles for the treatment of inflammation
|
US5474995A
(en)
*
|
1993-06-24 |
1995-12-12 |
Merck Frosst Canada, Inc. |
Phenyl heterocycles as cox-2 inhibitors
|
US5840746A
(en)
*
|
1993-06-24 |
1998-11-24 |
Merck Frosst Canada, Inc. |
Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
|
GB9602877D0
(en)
*
|
1996-02-13 |
1996-04-10 |
Merck Frosst Canada Inc |
3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
|
CA2180651A1
(en)
*
|
1994-01-10 |
1995-07-13 |
Yves Ducharme |
Phenyl heterocycles as cox-2 inhibitors
|
CA2195847A1
(en)
*
|
1994-07-27 |
1996-02-08 |
John J. Talley |
Substituted thiazoles for the treatment of inflammation
|
US6426360B1
(en)
*
|
1994-07-28 |
2002-07-30 |
G D Searle & Co. |
4,5-substituted imidazolyl compounds for the treatment of inflammation
|
US5616601A
(en)
*
|
1994-07-28 |
1997-04-01 |
Gd Searle & Co |
1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
|
US6613789B2
(en)
|
1994-07-28 |
2003-09-02 |
G. D. Searle & Co. |
Heterocyclo-substituted imidazoles for the treatment of inflammation
|
US5620999A
(en)
*
|
1994-07-28 |
1997-04-15 |
Weier; Richard M. |
Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
|
US6239172B1
(en)
*
|
1997-04-10 |
2001-05-29 |
Nitrosystems, Inc. |
Formulations for treating disease and methods of using same
|
GB2294879A
(en)
*
|
1994-10-19 |
1996-05-15 |
Merck & Co Inc |
Cylcooxygenase-2 Inhibitors
|
CA2200462A1
(en)
*
|
1994-10-27 |
1996-05-09 |
Merck Frosst Canada Inc. |
Stilbene derivatives useful as cyclooxygenase-2 inhibitors
|
JP2636819B2
(ja)
*
|
1994-12-20 |
1997-07-30 |
日本たばこ産業株式会社 |
オキサゾール系複素環式芳香族化合物
|
AU702591B2
(en)
*
|
1994-12-21 |
1999-02-25 |
Merck Frosst Canada Ltd. |
Diaryl-2-(5H)-furanones as cox-2 inhibitors
|
US5633272A
(en)
*
|
1995-02-13 |
1997-05-27 |
Talley; John J. |
Substituted isoxazoles for the treatment of inflammation
|
CN1107058C
(zh)
*
|
1995-02-13 |
2003-04-30 |
G·D·瑟尔公司 |
用于治疗类症的取代的异噁唑
|
US5691374A
(en)
*
|
1995-05-18 |
1997-11-25 |
Merck Frosst Canada Inc. |
Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
|
US6512121B2
(en)
|
1998-09-14 |
2003-01-28 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
CA2223154A1
(en)
|
1995-06-02 |
1996-12-05 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US6515014B2
(en)
|
1995-06-02 |
2003-02-04 |
G. D. Searle & Co. |
Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US5643933A
(en)
*
|
1995-06-02 |
1997-07-01 |
G. D. Searle & Co. |
Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US6156776A
(en)
*
|
1995-06-08 |
2000-12-05 |
Yu; Dingwei Tim |
Diaryl substituted thiazoles useful in the treatment of fungal infections
|
US5700816A
(en)
*
|
1995-06-12 |
1997-12-23 |
Isakson; Peter C. |
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
|
US6342510B1
(en)
|
1995-06-12 |
2002-01-29 |
G. D. Searle & Co. |
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
|
EP0833622B8
(en)
*
|
1995-06-12 |
2005-10-12 |
G.D. Searle & Co. |
Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
|
US6593361B2
(en)
|
1995-07-19 |
2003-07-15 |
Merck & Co Inc |
Method of treating colonic adenomas
|
US5968974A
(en)
|
1995-07-19 |
1999-10-19 |
Merck & Co., Inc. |
Method of treating colonic adenomas
|
US5792778A
(en)
*
|
1995-08-10 |
1998-08-11 |
Merck & Co., Inc. |
2-substituted aryl pyrroles, compositions containing such compounds and methods of use
|
US5837719A
(en)
*
|
1995-08-10 |
1998-11-17 |
Merck & Co., Inc. |
2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
|
US5786515A
(en)
*
|
1995-09-15 |
1998-07-28 |
Merck & Co., Inc. |
Synthesis of α-chloro or fluoro ketones
|
AU6981996A
(en)
*
|
1995-09-27 |
1997-04-17 |
Merck Frosst Canada Inc. |
Compositions for treating inflammation containing certain prostaglandins and a selective cyclooxygenase-2 inhibitor
|
US5717100A
(en)
*
|
1995-10-06 |
1998-02-10 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
US6083949A
(en)
*
|
1995-10-06 |
2000-07-04 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
US5981576A
(en)
*
|
1995-10-13 |
1999-11-09 |
Merck Frosst Canada, Inc. |
(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
|
US6020343A
(en)
*
|
1995-10-13 |
2000-02-01 |
Merck Frosst Canada, Inc. |
(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
|
UA57002C2
(uk)
*
|
1995-10-13 |
2003-06-16 |
Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. |
Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
|
KR19990064310A
(ko)
*
|
1995-10-17 |
1999-07-26 |
윌리암스 로저 에이 |
시클로옥시게나제-2의 검출방법
|
ATE212343T1
(de)
*
|
1995-10-30 |
2002-02-15 |
Merck Frosst Canada Inc |
3,4-diaryl-2-hydroxy-2,5-dihydrofurane als wirkstoffvorstufen von cox-2 inhibitoren
|
US6222048B1
(en)
*
|
1995-12-18 |
2001-04-24 |
Merck Frosst Canada & Co. |
Diaryl-2-(5H)-furanones as Cox-2 inhibitors
|
DE69737042T8
(de)
*
|
1996-01-26 |
2007-11-22 |
G.D. Searle Llc |
Ein Verfahren zur Herstellung von 4-[2-(Aryl oder Heterocyclo)-1H-imidazol-1-yl]benzolsulfonamiden
|
US5733909A
(en)
*
|
1996-02-01 |
1998-03-31 |
Merck Frosst Canada, Inc. |
Diphenyl stilbenes as prodrugs to COX-2 inhibitors
|
AU710675B2
(en)
*
|
1996-02-01 |
1999-09-30 |
Merck Frosst Canada Ltd. |
Alkylated styrenes as prodrugs to COX-2 inhibitors
|
US5789413A
(en)
*
|
1996-02-01 |
1998-08-04 |
Merck Frosst Canada, Inc. |
Alkylated styrenes as prodrugs to COX-2 inhibitors
|
EA199800675A1
(ru)
*
|
1996-02-01 |
1999-02-25 |
Мерк Фросст Кэнада Инк. |
Дифенилстильбены как пролекарства к ингибиторам циклооксигеназы(сох-2)
|
EP0880363B1
(en)
|
1996-02-13 |
2002-09-11 |
G.D. SEARLE & CO. |
Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a 4 hydrolase inhibitor
|
CA2246356A1
(en)
|
1996-02-13 |
1997-08-21 |
G.D. Searle & Co. |
Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist
|
CA2246265A1
(en)
|
1996-02-13 |
1997-08-21 |
G.D. Searle & Co. |
Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
|
KR100485642B1
(ko)
*
|
1996-03-18 |
2005-09-30 |
에자이 가부시키가이샤 |
축합고리함유카르복실산유도체
|
CA2250350A1
(en)
*
|
1996-03-29 |
1997-10-09 |
Merck Frosst Canada Inc. |
Bisarylcyclobutene derivates as cyclooxygenase inhibitors
|
US6180651B1
(en)
*
|
1996-04-04 |
2001-01-30 |
Bristol-Myers Squibb |
Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
|
US5807873A
(en)
*
|
1996-04-04 |
1998-09-15 |
Laboratories Upsa |
Diarylmethylidenefuran derivatives and their uses in therapeutics
|
FR2747123B1
(fr)
*
|
1996-04-04 |
1998-06-26 |
Union Pharma Scient Appl |
Nouveaux derives diarylmethylidene tetrahydrofurane, leurs procedes de preparation, et leurs utilisations en therapeutique
|
US5908858A
(en)
*
|
1996-04-05 |
1999-06-01 |
Sankyo Company, Limited |
1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
|
PL195955B1
(pl)
*
|
1996-04-12 |
2007-11-30 |
Searle & Co |
Związek, pochodna benzenosulfonamidu, sposób jegowytwarzania, kompozycja farmaceutyczna zawierająca go oraz jego zastosowanie
|
AU709609B2
(en)
*
|
1996-04-23 |
1999-09-02 |
Merck Frosst Canada & Co. |
Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
|
US5922742A
(en)
*
|
1996-04-23 |
1999-07-13 |
Merck Frosst Canada |
Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
|
BR9709097A
(pt)
*
|
1996-05-17 |
1999-08-03 |
Merck & Co Inc |
Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária
|
AU775030B2
(en)
*
|
1996-05-17 |
2004-07-15 |
Merck Frosst Company |
Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
|
CA2254121A1
(en)
*
|
1996-05-17 |
1997-11-27 |
Bruno Hancock |
Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
|
US5883267A
(en)
*
|
1996-05-31 |
1999-03-16 |
Merck & Co., Inc. |
Process for making phenyl heterocycles useful as cox-2 inhibitors
|
HRP970289A2
(en)
*
|
1996-05-31 |
1998-04-30 |
Merck & Co Inc |
Process for preparing phenyl heterocycles useful as cox-2 inhibitors
|
US6677364B2
(en)
|
1998-04-20 |
2004-01-13 |
G.D. Searle & Co. |
Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
AU708883B2
(en)
*
|
1996-06-10 |
1999-08-12 |
Merck & Co., Inc. |
Substituted imidazoles having cytokine inhibitory activity
|
GB9615867D0
(en)
*
|
1996-07-03 |
1996-09-11 |
Merck & Co Inc |
Process of preparing phenyl heterocycles useful as cox-2 inhibitors
|
US5677318A
(en)
*
|
1996-07-11 |
1997-10-14 |
Merck Frosst Canada, Inc. |
Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
|
DE69717281T2
(de)
*
|
1996-08-14 |
2003-09-04 |
G.D. Searle & Co., Chicago |
Kristalline form von 4-[5-methyl-3-phenylisoxazol-4-yl]benzolsulfonamid
|
US6586458B1
(en)
*
|
1996-08-16 |
2003-07-01 |
Pozen Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
US8022095B2
(en)
*
|
1996-08-16 |
2011-09-20 |
Pozen, Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
US5939069A
(en)
*
|
1996-08-23 |
1999-08-17 |
University Of Florida |
Materials and methods for detection and treatment of immune system dysfunctions
|
FR2753449B1
(fr)
*
|
1996-09-13 |
1998-12-04 |
Union Pharma Scient Appl |
Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
|
ES2224222T3
(es)
|
1996-10-15 |
2005-03-01 |
G.D. Searle Llc |
Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de neoplasias.
|
US5776954A
(en)
*
|
1996-10-30 |
1998-07-07 |
Merck & Co., Inc. |
Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
|
US5985930A
(en)
|
1996-11-21 |
1999-11-16 |
Pasinetti; Giulio M. |
Treatment of neurodegenerative conditions with nimesulide
|
US5935990A
(en)
*
|
1996-12-10 |
1999-08-10 |
G.D. Searle & Co. |
Substituted pyrrolyl compounds for the treatment of inflammation
|
EP0863134A1
(en)
*
|
1997-03-07 |
1998-09-09 |
Merck Frosst Canada Inc. |
2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
|
DE69825154T2
(de)
*
|
1997-03-14 |
2005-07-21 |
Merck Frosst Canada & Co, Kirkland |
Pyridazinone als inhibitoren von cyclooxygenase-2
|
ES2201466T3
(es)
*
|
1997-03-14 |
2004-03-16 |
MERCK FROSST CANADA & CO. |
`(metilsulfonil)fenil-2-(5h)-furanonas con enlace con oxigeno como inhibidores de cox-2`.
|
US6004960A
(en)
*
|
1997-03-14 |
1999-12-21 |
Merck Frosst Canada, Inc. |
Pyridazinones as inhibitors of cyclooxygenase-2
|
US6071954A
(en)
*
|
1997-03-14 |
2000-06-06 |
Merk Frosst Canada, Inc. |
(methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
|
US6130334A
(en)
*
|
1998-04-15 |
2000-10-10 |
Merck & Co., Inc. |
Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
|
TW492959B
(en)
*
|
1997-04-18 |
2002-07-01 |
Merck & Co Inc |
Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors
|
US6127545A
(en)
*
|
1997-04-18 |
2000-10-03 |
Merck & Co., Inc. |
Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
|
US20040072889A1
(en)
*
|
1997-04-21 |
2004-04-15 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
|
US6525053B1
(en)
|
1997-08-22 |
2003-02-25 |
Abbott Laboratories |
Prostaglandin endoperoxide H synthase biosynthesis inhibitors
|
US6307047B1
(en)
*
|
1997-08-22 |
2001-10-23 |
Abbott Laboratories |
Prostaglandin endoperoxide H synthase biosynthesis inhibitors
|
EP1510519B1
(en)
*
|
1997-09-05 |
2006-02-15 |
Glaxo Group Limited |
Pharmaceutical compositions comprising 2,3-diarylpyrazolo[1,5-B]pyridazine derivatives
|
US6004950A
(en)
*
|
1997-09-12 |
1999-12-21 |
Merck Frosst Canada, Inc. |
2-aminopyridines as inhibitors of cyclooxygenase-2
|
ATE293602T1
(de)
*
|
1997-09-12 |
2005-05-15 |
Merck Frosst Canada Inc |
2-aminopyridine als inhibitoren von cyclooxygenase-2
|
RS49982B
(sr)
*
|
1997-09-17 |
2008-09-29 |
Euro-Celtique S.A., |
Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
|
US6034089A
(en)
*
|
1997-10-03 |
2000-03-07 |
Merck & Co., Inc. |
Aryl thiophene derivatives as PDE IV inhibitors
|
US6020339A
(en)
*
|
1997-10-03 |
2000-02-01 |
Merck & Co., Inc. |
Aryl furan derivatives as PDE IV inhibitors
|
FR2769311B1
(fr)
*
|
1997-10-07 |
1999-12-24 |
Union Pharma Scient Appl |
Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
|
US5972986A
(en)
*
|
1997-10-14 |
1999-10-26 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
|
US6080876A
(en)
*
|
1997-10-29 |
2000-06-27 |
Merck & Co., Inc. |
Process for making phenyl heterocycles useful as COX-2 inhibitors
|
JP2001521932A
(ja)
*
|
1997-10-30 |
2001-11-13 |
メルク フロスト カナダ アンド カンパニー |
選択的シクロオキシゲナーゼ−2−阻害剤としてのジアリール−5−アルキル−5−メチル−2(5h)−フラノン
|
US6133292A
(en)
*
|
1997-10-30 |
2000-10-17 |
Merck Frosst Canada & Co. |
Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
|
AU758566B2
(en)
*
|
1997-10-31 |
2003-03-27 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor
|
US6025353A
(en)
*
|
1997-11-19 |
2000-02-15 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
|
CA2313049A1
(en)
|
1997-12-17 |
1999-06-24 |
Cornell Research Foundation, Inc. |
Cyclooxygenase-2 inhibition
|
US7041694B1
(en)
|
1997-12-17 |
2006-05-09 |
Cornell Research Foundation, Inc. |
Cyclooxygenase-2 inhibition
|
SI1685839T1
(sl)
|
1997-12-22 |
2013-08-30 |
Euro-Celtique S.A. |
Farmacevtska oralna dozirna oblika, ki vsebuje kombinacijo opioidnega agonista in opioidnega antagonista
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
US6887893B1
(en)
|
1997-12-24 |
2005-05-03 |
Sankyo Company, Limited |
Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
|
FR2775477B1
(fr)
*
|
1998-02-27 |
2000-05-19 |
Union Pharma Scient Appl |
Nouveaux derives diarylmethylene heterocycliques, leurs procedes de preparation et leurs utilisations en therapeutique
|
US6136804A
(en)
|
1998-03-13 |
2000-10-24 |
Merck & Co., Inc. |
Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
|
US6727238B2
(en)
|
1998-06-11 |
2004-04-27 |
Pfizer Inc. |
Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
|
US6294558B1
(en)
|
1999-05-31 |
2001-09-25 |
Pfizer Inc. |
Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
|
TNSN99111A1
(fr)
*
|
1998-06-11 |
2005-11-10 |
Pfizer |
Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
|
WO2000012093A1
(en)
*
|
1998-08-31 |
2000-03-09 |
Merck & Co., Inc. |
Method of treating neurodegenerative diseases
|
DE19842833B4
(de)
*
|
1998-09-18 |
2005-04-14 |
Merckle Gmbh |
2-Arylalkylthio-imidazole, 2-Arylalkenylthio-imidazole und 2-Arylalkinylthio-imidazole als Entzündungs-Hemmstoffe und Hemmstoffe der Cytokin-Freisetzung
|
CA2347768A1
(en)
*
|
1998-10-27 |
2000-05-04 |
Merck & Co., Inc. |
Synthesis of methylthiophenyl hydroxyketones
|
CA2348979A1
(en)
*
|
1998-11-02 |
2000-05-11 |
Merck & Co., Inc. |
Method of treating migraines and pharmaceutical compositions
|
DE69919887T2
(de)
|
1998-11-03 |
2005-09-15 |
Glaxo Group Ltd., Greenford |
Pyrazolopyridin derivative als selektive cox-2 inhibitoren
|
SA99191255B1
(ar)
*
|
1998-11-30 |
2006-11-25 |
جي دي سيرل اند كو |
مركبات سيليكوكسيب celecoxib
|
US20040122011A1
(en)
*
|
1998-12-23 |
2004-06-24 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
|
US6649645B1
(en)
*
|
1998-12-23 |
2003-11-18 |
Pharmacia Corporation |
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
US6155267A
(en)
*
|
1998-12-31 |
2000-12-05 |
Medtronic, Inc. |
Implantable medical device monitoring method and system regarding same
|
WO2000044225A1
(en)
*
|
1999-01-27 |
2000-08-03 |
Cornell Research Foundation, Inc. |
TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/neu
|
JP2002538157A
(ja)
|
1999-02-27 |
2002-11-12 |
グラクソ グループ リミテッド |
ピラゾロピリジン
|
US6277873B1
(en)
|
1999-03-25 |
2001-08-21 |
Dingwei Tim Yu |
Oxadiazole antifungal agents
|
ATE256672T1
(de)
*
|
1999-04-14 |
2004-01-15 |
Pacific Corp |
4,5-diaryl-3(2h)-furanon derivate als cyclooxygenase-2 inhibitoren
|
KR20010094161A
(ko)
*
|
2000-04-04 |
2001-10-31 |
서경배 |
2,2-디메틸-4,5-디아릴-3(2h)퓨라논의 유도체 및 이를함유하는 선택적인 시클로옥시게네이즈-2 저해제로서약제학적 조성물
|
CO5261541A1
(es)
*
|
1999-05-14 |
2003-03-31 |
Pfizer Prod Inc |
Terapia de combinacion para el tratamiento de la migrana
|
CO5190664A1
(es)
|
1999-06-30 |
2002-08-29 |
Pfizer Prod Inc |
Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
|
US6066667A
(en)
*
|
1999-08-17 |
2000-05-23 |
Ashbrook; Charles D. |
Substituted furanones, compositions and antiarthritic use
|
WO2001017996A1
(en)
*
|
1999-09-08 |
2001-03-15 |
Merck Frosst Canada & Co. |
1,2,3-thiadiazoles and their use as cox-2 inhibitors
|
CA2382547A1
(en)
*
|
1999-09-21 |
2001-03-29 |
Stephen R. Hanson |
Methods and compositions for treating platelet-related disosders
|
DE69940922D1
(de)
*
|
1999-10-08 |
2009-07-09 |
Merial Sas |
Polymorphe Form B von 3-(Cyclopropylmethoxy)-4-i4-(methylsulfonyl)phenyl -5,5-dimethyl-5H-furan-2-on
|
EP1099695A1
(en)
*
|
1999-11-09 |
2001-05-16 |
Laboratoire Theramex S.A. |
5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
|
TR200302047T4
(tr)
|
1999-12-03 |
2004-01-21 |
Pfizer Products Inc. |
Anti-iltihabik / analjezik maddeler olarak heteroaril fenil pirazol bileşikleri.
|
ES2193921T3
(es)
|
1999-12-03 |
2003-11-16 |
Pfizer Prod Inc |
Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
|
DE60004001T2
(de)
|
1999-12-03 |
2004-04-15 |
Pfizer Products Inc., Groton |
Acetylenderivate zur Verwendung als schmerzstillendes oder entzündungshemmendes Mittel
|
ATE291019T1
(de)
|
1999-12-03 |
2005-04-15 |
Pfizer Prod Inc |
Heterocyclo-alkylsulfonylpyrazolderivate zur verwendung als anti-imflammatorische oder analgetische verbindungen
|
UA74539C2
(en)
|
1999-12-08 |
2006-01-16 |
Pharmacia Corp |
Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
|
OA11831A
(en)
*
|
1999-12-08 |
2005-08-23 |
Pharmacia Corp |
Polymorphic crystalline forms of celecoxib.
|
PL351944A1
(en)
*
|
1999-12-08 |
2003-07-14 |
Pharmacia Corp |
Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
|
GB9930358D0
(en)
|
1999-12-22 |
2000-02-09 |
Glaxo Group Ltd |
Process for the preparation of chemical compounds
|
US6649629B2
(en)
*
|
1999-12-23 |
2003-11-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
|
DE10001166A1
(de)
|
2000-01-13 |
2001-07-19 |
Merckle Gmbh |
Anellierte Pyrrolverbindungen, diese enthaltende pharmazeutische Mittel und deren Verwendung
|
WO2001056596A1
(en)
|
2000-02-04 |
2001-08-09 |
Children's Hospital Research Foundation |
Use of lysosomal acid lipase for treating atherosclerosis and related diseases
|
NZ520554A
(en)
|
2000-02-08 |
2005-08-26 |
Euro Celtique S |
Tamper-resistant oral opioid agonist formulations
|
PL357158A1
(en)
|
2000-02-08 |
2004-07-12 |
Euro-Celtique, S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
ES2166710B1
(es)
*
|
2000-04-25 |
2004-10-16 |
J. URIACH & CIA, S.A. |
Nuevos compuestos heterociclicos con actividad antiinflamatoria.
|
JP2003531202A
(ja)
|
2000-04-25 |
2003-10-21 |
ファルマシア・コーポレーション |
3,4−ジ(カルボシクリルまたはヘテロシクリル)チオフェンの位置選択的合成
|
CN1443180A
(zh)
*
|
2000-05-22 |
2003-09-17 |
雷迪实验室有限公司 |
具有抗炎活性的新的化合物:它们的制备方法和含有它们的药物组合物
|
EA200802070A1
(ru)
*
|
2000-06-13 |
2009-06-30 |
Вайет |
Болеутоляющее и противовоспалительные составы, содержащие ингибиторы циклооксигеназы-2
|
US6465509B2
(en)
*
|
2000-06-30 |
2002-10-15 |
Merck Frosst Canada & Co. |
Pyrones as inhibitors of cyclooxygenase-2
|
WO2002005848A2
(en)
*
|
2000-07-13 |
2002-01-24 |
Pharmacia Corporation |
Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
NZ524252A
(en)
*
|
2000-07-20 |
2004-03-26 |
Lauras As |
Cox-2 inhibitors for treating HIV and AIDS
|
US6716829B2
(en)
|
2000-07-27 |
2004-04-06 |
Pharmacia Corporation |
Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
|
PE20020506A1
(es)
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
AU2001285334A1
(en)
*
|
2000-08-29 |
2002-03-13 |
Peter Van Patten |
Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
|
GB0021494D0
(en)
*
|
2000-09-01 |
2000-10-18 |
Glaxo Group Ltd |
Chemical comkpounds
|
US20030219461A1
(en)
*
|
2000-09-12 |
2003-11-27 |
Britten Nancy J. |
Parenteral combination therapy for infective conditions
|
AU2001295038A1
(en)
*
|
2000-09-18 |
2002-03-26 |
Merck & Co., Inc. |
Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-V antagonist
|
DE10057366A1
(de)
*
|
2000-11-18 |
2002-05-23 |
Mahle Gmbh |
Verfahren zur gießtechnischen Herstellung eines Kolbens mit einem gekühlten Ringträger
|
DE60112609T2
(de)
|
2000-12-15 |
2006-01-19 |
Glaxo Group Ltd., Greenford |
Pyrazolopyridine
|
ES2243579T3
(es)
|
2000-12-15 |
2005-12-01 |
Glaxo Group Ltd |
Derivados de pirazolopirideno.
|
CA2432642A1
(en)
|
2000-12-21 |
2002-08-08 |
Subhash P. Khanapure |
Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
AUPR283801A0
(en)
*
|
2001-02-01 |
2001-03-01 |
Australian National University, The |
Chemical compounds and methods
|
US20030008870A1
(en)
*
|
2001-02-02 |
2003-01-09 |
Joel Krasnow |
Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dysmenorrhea
|
DE10107683A1
(de)
|
2001-02-19 |
2002-08-29 |
Merckle Gmbh Chem Pharm Fabrik |
2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
|
ATE274515T1
(de)
|
2001-03-08 |
2004-09-15 |
Smithkline Beecham Corp |
Pyrazolopyridinderivate
|
US7034030B2
(en)
|
2001-03-30 |
2006-04-25 |
Smithkline Beecham Corporation |
Pyralopyridines, process for their preparation and use as therapeutic compounds
|
US7695736B2
(en)
|
2001-04-03 |
2010-04-13 |
Pfizer Inc. |
Reconstitutable parenteral composition
|
WO2002083672A1
(en)
|
2001-04-10 |
2002-10-24 |
Smithkline Beecham Corporation |
Antiviral pyrazolopyridine compounds
|
US20030105144A1
(en)
|
2001-04-17 |
2003-06-05 |
Ping Gao |
Stabilized oral pharmaceutical composition
|
US6673818B2
(en)
|
2001-04-20 |
2004-01-06 |
Pharmacia Corporation |
Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
|
US6756498B2
(en)
|
2001-04-27 |
2004-06-29 |
Smithkline Beecham Corporation |
Process for the preparation of chemical compounds
|
DE60204452T2
(de)
|
2001-04-27 |
2005-12-15 |
Smithkline Beecham Corp. |
Pyrazolo[1,5a]Pyridinderivate
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US20040132780A1
(en)
*
|
2001-05-04 |
2004-07-08 |
Allen Christopher P. |
Method and compositions for treating migraines
|
CN1525851A
(zh)
|
2001-05-11 |
2004-09-01 |
������ҩ������˾ |
抗滥用阿片样物质控释剂型
|
GB0112810D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Glaxo Group Ltd |
Pyrimidine derivatives
|
GB0112802D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Glaxo Group Ltd |
Pyrimidine derivatives
|
US20030153801A1
(en)
*
|
2001-05-29 |
2003-08-14 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
|
PL367337A1
(en)
*
|
2001-05-31 |
2005-02-21 |
Pharmacia Corporation |
Skin-permeable selective cyclooxygenase-2 inhibitor composition
|
DE10129320A1
(de)
*
|
2001-06-19 |
2003-04-10 |
Norbert Mueller |
Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
|
US20060167074A1
(en)
*
|
2001-06-19 |
2006-07-27 |
Norbert Muller |
Methods and compositions for the treatment of psychiatric disorders
|
EP1401836B1
(en)
|
2001-06-21 |
2006-08-23 |
SmithKline Beecham Corporation |
Imidazo¬1,2-a|pyridine derivatives for the prophylaxis and treatment of herpes viral infections
|
EP1273582B1
(en)
|
2001-07-05 |
2005-06-29 |
Pfizer Products Inc. |
Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents
|
DK1416842T3
(da)
|
2001-07-18 |
2009-03-16 |
Euro Celtique Sa |
Farmaceutiske kombinationer af oxycodon og naloxon
|
US20030157168A1
(en)
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
DE60232417D1
(de)
|
2001-08-06 |
2009-07-02 |
Euro Celtique Sa |
Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
GB0119477D0
(en)
*
|
2001-08-09 |
2001-10-03 |
Glaxo Group Ltd |
Pyrimidine derivatives
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
WO2003018575A1
(en)
*
|
2001-08-24 |
2003-03-06 |
Wyeth Holdings Corporation |
5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase
|
US20030114483A1
(en)
*
|
2001-09-18 |
2003-06-19 |
Pharmacia Corporation |
Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
US20030236308A1
(en)
*
|
2001-09-18 |
2003-12-25 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
KR20040044990A
(ko)
*
|
2001-09-26 |
2004-05-31 |
파마시아 코포레이션 |
구강내 붕해성 발데콕시브 조성물
|
GT200200183A
(es)
|
2001-09-28 |
2003-05-23 |
|
Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol
|
DE60211539T2
(de)
|
2001-10-05 |
2006-09-21 |
Smithkline Beecham Corp. |
Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
|
KR100810468B1
(ko)
|
2001-10-10 |
2008-03-07 |
씨제이제일제당 (주) |
사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1h-인돌 유도체
|
KR100824233B1
(ko)
|
2001-10-10 |
2008-04-24 |
씨제이제일제당 (주) |
사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난3,4-디하이드로-1h-나프탈렌 유도체
|
WO2003037336A1
(en)
|
2001-11-02 |
2003-05-08 |
Pfizer Products Inc. |
1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
|
CA2468266A1
(en)
|
2001-12-06 |
2003-06-19 |
Merck & Co., Inc. |
Substituted bicyclic pyrimidinones as a mitotic kinesin ksp inhibitors
|
FR2833164B1
(fr)
*
|
2001-12-07 |
2004-07-16 |
Oreal |
Compositions cosmetiques antisolaires a base d'un melange synergique de filtres et utilisations
|
DE60222465T2
(de)
|
2001-12-11 |
2008-06-05 |
Smithkline Beecham Corp. |
Pyrazolopyridin-derivate als antiherpesmittel
|
DE10162120A1
(de)
*
|
2001-12-12 |
2003-06-18 |
Berolina Drug Dev Ab Svedala |
Deuterierte substituierte Dihydrofuranone sowie diese Verbindungen enthaltende Arzneimittel
|
US20040082940A1
(en)
*
|
2002-10-22 |
2004-04-29 |
Michael Black |
Dermatological apparatus and method
|
US20030212138A1
(en)
*
|
2002-01-14 |
2003-11-13 |
Pharmacia Corporation |
Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
|
US20030220374A1
(en)
*
|
2002-01-14 |
2003-11-27 |
Pharmacia Corporation |
Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
|
US7985771B2
(en)
*
|
2002-01-31 |
2011-07-26 |
Monsanto Technology Llc |
Furanone derivatives
|
US6667330B2
(en)
|
2002-01-31 |
2003-12-23 |
Galileo Pharmaceuticals, Inc. |
Furanone derivatives
|
KR20040098050A
(ko)
|
2002-04-05 |
2004-11-18 |
유로-셀띠끄 소시에떼 아노님 |
옥시코돈 및 날록손을 포함하는 약제학적 제제
|
PL372962A1
(en)
*
|
2002-04-08 |
2005-08-08 |
Glaxo Group Limited |
(2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives
|
IL164163A0
(en)
*
|
2002-04-09 |
2005-12-18 |
Pharmacia Corp |
Process for preparing a finely self-emulsifiable pharmaceutical composition
|
US7329401B2
(en)
|
2002-04-15 |
2008-02-12 |
The Regents Of The University Of California |
Cyclooxygenase-2 selective agents useful as imaging probes and related methods
|
JP2005532792A
(ja)
|
2002-04-17 |
2005-11-04 |
ザ クリーブランド クリニック ファウンデーション |
治療薬剤の抗炎症作用および抗酸化作用をモニターするための全身マーカー
|
JP2005535576A
(ja)
*
|
2002-04-22 |
2005-11-24 |
ファイザー・プロダクツ・インク |
シクロオキシゲナーゼ−2の選択的阻害薬としてのインドール−2−オン類
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
HUE039881T2
(hu)
|
2002-05-09 |
2019-02-28 |
Brigham & Womens Hospital Inc |
1L1RL-1, mint egy kardiovaszkuláris betegség-marker
|
US7273616B2
(en)
*
|
2002-05-10 |
2007-09-25 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof
|
KR100804827B1
(ko)
*
|
2002-05-17 |
2008-02-20 |
씨제이제일제당 (주) |
티아졸리딘-4-온 유도체, 그 제조방법 및 약제학적 조성물
|
US20030225054A1
(en)
*
|
2002-06-03 |
2003-12-04 |
Jingwu Duan |
Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
|
KR100465455B1
(ko)
*
|
2002-06-24 |
2005-01-13 |
씨제이 주식회사 |
2-티옥소티아졸 유도체, 그 제조방법 및 약제학적 조성물
|
KR100478467B1
(ko)
|
2002-06-24 |
2005-03-23 |
씨제이 주식회사 |
피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물
|
EP1534683A4
(en)
*
|
2002-06-27 |
2005-08-24 |
Nitromed Inc |
CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHOD OF USE
|
WO2004002420A2
(en)
*
|
2002-06-28 |
2004-01-08 |
Nitromed, Inc. |
Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
|
MXPA05000259A
(es)
*
|
2002-07-02 |
2005-04-11 |
Pharmacia Corp |
Uso de inhibidores selectivos de ciclooxigenasa-2 y agentes tromboliticos para el tratamiento o prevencion de un evento vaso-oclusivo.
|
KR100467668B1
(ko)
|
2002-08-07 |
2005-01-24 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
EP1546128B1
(en)
*
|
2002-08-19 |
2006-05-03 |
Glaxo Group Limited |
Pyrimidine derivatives as selective cox-2 inhibitors
|
DE10238045A1
(de)
|
2002-08-20 |
2004-03-04 |
Merckle Gmbh Chem.-Pharm. Fabrik |
2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
GB0221443D0
(en)
|
2002-09-16 |
2002-10-23 |
Glaxo Group Ltd |
Pyridine derivates
|
PT1551372T
(pt)
|
2002-09-20 |
2018-07-23 |
Alpharma Pharmaceuticals Llc |
Subunidade de sequestração e composições e métodos relacionados
|
US8303511B2
(en)
*
|
2002-09-26 |
2012-11-06 |
Pacesetter, Inc. |
Implantable pressure transducer system optimized for reduced thrombosis effect
|
WO2004033454A1
(en)
|
2002-10-03 |
2004-04-22 |
Smithkline Beecham Corporation |
Therapeutic compounds based on pyrazolopyridine derivatives
|
DK1556083T3
(da)
*
|
2002-10-08 |
2011-04-04 |
Rinat Neuroscience Corp |
Fremgangsmåde til behandling af post-operative smerter ved indgivelse af en antistof mod nervevækstfaktor og sammensætning indeholdende samme
|
AU2003304238A1
(en)
|
2002-10-08 |
2005-01-13 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
KR100484525B1
(ko)
*
|
2002-10-15 |
2005-04-20 |
씨제이 주식회사 |
이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
|
US20040082543A1
(en)
*
|
2002-10-29 |
2004-04-29 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
|
AU2003284981B2
(en)
*
|
2002-10-30 |
2009-05-28 |
Merck Sharp & Dohme Corp. |
Inhibitors of Akt activity
|
GB0225548D0
(en)
*
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Compounds
|
AU2003283096A1
(en)
*
|
2002-11-05 |
2004-06-07 |
Merck Frosst Canada And Co. |
Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
|
WO2004043358A2
(en)
*
|
2002-11-08 |
2004-05-27 |
Bristol-Myers Squibb Company |
Formulations of low solubility bioactive agents and processes for making the same
|
US20040147581A1
(en)
*
|
2002-11-18 |
2004-07-29 |
Pharmacia Corporation |
Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
|
KR100470075B1
(ko)
|
2002-11-21 |
2005-02-05 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
GB0227443D0
(en)
*
|
2002-11-25 |
2002-12-31 |
Glaxo Group Ltd |
Pyrimidine derivatives
|
KR100491317B1
(ko)
|
2002-11-26 |
2005-05-24 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
KR100470076B1
(ko)
|
2002-11-27 |
2005-02-05 |
씨제이 주식회사 |
1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
|
DE60332387D1
(de)
|
2002-12-13 |
2010-06-10 |
Warner Lambert Co |
Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
|
CN1726018A
(zh)
*
|
2002-12-19 |
2006-01-25 |
法玛西雅公司 |
使用环加氧酶-2选择性抑制剂或环加氧酶-2抑制剂联合抗病毒剂治疗疱疹病毒感染的方法和组合物
|
WO2004058354A1
(en)
*
|
2002-12-20 |
2004-07-15 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
|
ES2215474B1
(es)
*
|
2002-12-24 |
2005-12-16 |
J. URIACH & CIA S.A. |
Nuevos derivados de fosforamida.
|
US7569364B2
(en)
*
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
WO2004058184A2
(en)
*
|
2002-12-24 |
2004-07-15 |
Rinat Neuroscience Corp. |
Anti-ngf antibodies and methods using same
|
MXPA05006954A
(es)
*
|
2002-12-26 |
2005-09-22 |
Pozen Inc |
Formas de dosificacion de capas multiples que contienen nsaids y triptanos.
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US20070265606A1
(en)
*
|
2003-02-14 |
2007-11-15 |
Reliant Technologies, Inc. |
Method and Apparatus for Fractional Light-based Treatment of Obstructive Sleep Apnea
|
EP1594441B1
(en)
|
2003-02-19 |
2010-12-15 |
Rinat Neuroscience Corp. |
Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same
|
US20040214753A1
(en)
*
|
2003-03-20 |
2004-10-28 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
KR100717433B1
(ko)
*
|
2003-03-20 |
2007-05-14 |
파마시아 코포레이션 |
소염제의 분산성 배합물
|
US20050004098A1
(en)
*
|
2003-03-20 |
2005-01-06 |
Britten Nancy Jean |
Dispersible formulation of an anti-inflammatory agent
|
US20050009931A1
(en)
*
|
2003-03-20 |
2005-01-13 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
US20040220155A1
(en)
*
|
2003-03-28 |
2004-11-04 |
Pharmacia Corporation |
Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
|
TWI347201B
(en)
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
US20050159403A1
(en)
*
|
2003-04-22 |
2005-07-21 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage
|
US20040229803A1
(en)
*
|
2003-04-22 |
2004-11-18 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
|
WO2004093814A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker
|
WO2004093813A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
|
US20050107387A1
(en)
*
|
2003-05-13 |
2005-05-19 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
|
WO2004105699A2
(en)
*
|
2003-05-28 |
2004-12-09 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
|
NZ543741A
(en)
|
2003-05-30 |
2009-10-30 |
Ranbaxy Lab Ltd |
Substituted pyrrole derivatives and their use as HMG-Co inhibitors
|
CN1309717C
(zh)
*
|
2003-06-03 |
2007-04-11 |
李小虎 |
4-芳基-5h-噻吩-2-酮衍生物、其制法和用途
|
EP1633402A2
(en)
*
|
2003-06-06 |
2006-03-15 |
Glaxo Group Limited |
Pharmaceutical composition
|
EP1638573A4
(en)
*
|
2003-06-20 |
2009-12-02 |
Merck & Co Inc |
USE OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS
|
US20050065154A1
(en)
*
|
2003-06-24 |
2005-03-24 |
Pharmacia Corporation |
Treatment of migraine accompanied by nausea with a combination of cyclooxygenase-2 selective inhibitors and anti-nausea agents
|
WO2005007106A2
(en)
*
|
2003-07-10 |
2005-01-27 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a non-nmda glutamate modulator for the treatment of central nervous system damage
|
US20050014729A1
(en)
*
|
2003-07-16 |
2005-01-20 |
Pharmacia Corporation |
Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
|
US20050075341A1
(en)
*
|
2003-07-17 |
2005-04-07 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
|
AU2004266705A1
(en)
*
|
2003-08-20 |
2005-03-03 |
Nitromed, Inc. |
Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
|
US20050119262A1
(en)
*
|
2003-08-21 |
2005-06-02 |
Pharmacia Corporation |
Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
|
US20050107350A1
(en)
*
|
2003-08-22 |
2005-05-19 |
Pharmacia Corporation |
Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
CA2536975A1
(en)
*
|
2003-08-28 |
2005-03-17 |
Nitromed, Inc. |
Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
|
EP1663184A2
(en)
|
2003-08-29 |
2006-06-07 |
The Brigham And Women's Hospital, Inc. |
Hydantoin derivatives as inhibitors of cellular necrosis
|
WO2005023189A2
(en)
*
|
2003-09-03 |
2005-03-17 |
Pharmacia Corporation |
Method of cox-2 selective inhibitor and nitric oxide-donating agent
|
US20050131028A1
(en)
*
|
2003-09-11 |
2005-06-16 |
Pharmacia Corporation |
Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
|
EP2298303A1
(en)
|
2003-09-25 |
2011-03-23 |
Euro-Celtique S.A. |
Pharmaceutical combinations of hydrocodone and naltrexone
|
GB0323581D0
(en)
*
|
2003-10-08 |
2003-11-12 |
Glaxo Group Ltd |
Novel compounds
|
GB0323585D0
(en)
*
|
2003-10-08 |
2003-11-12 |
Glaxo Group Ltd |
Compounds
|
GB0323584D0
(en)
*
|
2003-10-08 |
2003-11-12 |
Glaxo Group Ltd |
Compounds
|
FR2860792B1
(fr)
|
2003-10-10 |
2006-02-24 |
Sanofi Synthelabo |
Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique
|
WO2005044227A1
(en)
*
|
2003-11-05 |
2005-05-19 |
Glenmark Pharmaceuticals Limited |
Topical pharmaceutical compositions
|
US20050100594A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Nilendu Sen |
Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
|
DE602004028150D1
(de)
*
|
2003-11-26 |
2010-08-26 |
Pfizer Prod Inc |
Aminopyrazolderivate als gsk-3-inhibitoren
|
US7070816B2
(en)
*
|
2003-12-05 |
2006-07-04 |
New Chapter, Inc. |
Methods for treating prostatic intraepithelial neoplasia with herbal compositions
|
US7067159B2
(en)
*
|
2003-12-05 |
2006-06-27 |
New Chapter, Inc. |
Methods for treating prostate cancer with herbal compositions
|
EP1697746B1
(en)
|
2003-12-05 |
2012-02-22 |
The Cleveland Clinic Foundation |
Risk markers for cardiovascular disease
|
WO2005070006A2
(en)
*
|
2004-01-22 |
2005-08-04 |
Nitromed, Inc. |
Nitrosated and/or nitrosylated compounds, compositions and methods of use
|
US7449462B2
(en)
|
2004-01-22 |
2008-11-11 |
Pfizer, Inc. |
Triazole derivatives which inhibit vasopressin antagonistic activity
|
US20050203081A1
(en)
*
|
2004-02-25 |
2005-09-15 |
Jinbo Lee |
Inhibitors of protein tyrosine phosphatase 1B
|
AR047894A1
(es)
*
|
2004-02-25 |
2006-03-01 |
Wyeth Corp |
Derivados de tiofeno como inhibidores de la proteina tirosina fosfatasa 1b (ptpasa 1b); metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por ptpasa 1b
|
PL1732949T3
(pl)
*
|
2004-04-07 |
2010-06-30 |
Rinat Neuroscience Corp |
Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów
|
BRPI0510340A
(pt)
*
|
2004-04-28 |
2007-10-30 |
Pfizer |
derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina
|
US7507823B2
(en)
*
|
2004-05-06 |
2009-03-24 |
Bristol-Myers Squibb Company |
Process of making aripiprazole particles
|
GB0410121D0
(en)
*
|
2004-05-06 |
2004-06-09 |
Glaxo Group Ltd |
Compounds
|
US20080138282A1
(en)
*
|
2004-06-03 |
2008-06-12 |
The Trustees Of Columbia University In The City Of New York |
Radiolabeled Arylsulfonyl Compounds and Uses Thereof
|
EP1604666A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
ES2653568T3
(es)
|
2004-06-12 |
2018-02-07 |
Collegium Pharmaceutical, Inc. |
Formulaciones de fármacos para la prevención del abuso
|
AU2005262373B2
(en)
|
2004-07-01 |
2011-03-17 |
Merck Sharp & Dohme Corp. |
Mitotic kinesin inhibitors
|
ES2257929B1
(es)
*
|
2004-07-16 |
2007-05-01 |
Laboratorios Del Dr. Esteve, S.A. |
Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
|
WO2006011048A1
(en)
*
|
2004-07-22 |
2006-02-02 |
Pharmacia Corporation |
Compositions for treatment of inflammation and pain using a combination of a cox-2 selective inhibitor and a ltb4 receptor antagonist
|
WO2006137839A2
(en)
|
2004-08-24 |
2006-12-28 |
Merck & Co., Inc. |
Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
|
US7622142B2
(en)
*
|
2004-09-14 |
2009-11-24 |
New Chapter Inc. |
Methods for treating glioblastoma with herbal compositions
|
US20060064142A1
(en)
*
|
2004-09-17 |
2006-03-23 |
Cardiac Pacemakers, Inc. |
Systems and methods for deriving relative physiologic measurements using an implanted sensor device
|
US8067464B2
(en)
|
2004-10-04 |
2011-11-29 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
CA2624601C
(en)
|
2004-10-06 |
2018-07-03 |
The Brigham And Women's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
AU2005304770A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Nicox S.A. |
Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
|
WO2006055542A2
(en)
*
|
2004-11-15 |
2006-05-26 |
Nitromed, Inc. |
Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use
|
AR052429A1
(es)
|
2004-12-23 |
2007-03-21 |
Glaxo Group Ltd |
Compuesto de arilpiridina, composicion farmaceutica que lo comprende, su uso para l a eleboracion de un medicamento y procedimiento para prepararlo
|
US8481565B2
(en)
*
|
2004-12-27 |
2013-07-09 |
Eisai R&D Management Co., Ltd. |
Method for stabilizing anti-dementia drug
|
CA2595579A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Nitromed, Inc. |
Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
|
SG175477A1
(en)
*
|
2005-01-31 |
2011-11-28 |
Mylan Lab Inc |
Hydroxylated nebivolol metabolites
|
AU2006336387A1
(en)
*
|
2005-02-16 |
2007-08-02 |
Nicox S.A. |
Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
|
US7521435B2
(en)
*
|
2005-02-18 |
2009-04-21 |
Pharma Diagnostics, N.V. |
Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
|
EP1858863A1
(en)
*
|
2005-02-28 |
2007-11-28 |
Nitromed, Inc. |
Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
EP1861093A2
(en)
*
|
2005-03-09 |
2007-12-05 |
Nitromed, Inc. |
Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
|
WO2006110918A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Ambit Biosciences Corporation |
Pyrrole compounds and uses thereof
|
KR101213345B1
(ko)
*
|
2005-04-28 |
2012-12-17 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
항치매약을 함유하는 조성물
|
AU2006244393B2
(en)
*
|
2005-05-05 |
2012-06-21 |
Cook Biotech Incorporated |
Implantable materials and methods for inhibiting tissue adhesion formation
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
JP2008540633A
(ja)
*
|
2005-05-18 |
2008-11-20 |
ファイザー・リミテッド |
バソプレッシン拮抗薬としての1,2,4−トリアゾール誘導体
|
US20090048219A1
(en)
*
|
2005-05-23 |
2009-02-19 |
Nitromed Inc. |
Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
|
AP2896A
(en)
|
2005-05-31 |
2014-05-31 |
Mylan Lab Inc |
Compositions comprising nebivolol
|
WO2007016677A2
(en)
|
2005-08-02 |
2007-02-08 |
Nitromed, Inc. |
Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
|
TW200804345A
(en)
|
2005-08-30 |
2008-01-16 |
Novartis Ag |
Substituted benzimidazoles and methods of preparation
|
US20090054381A1
(en)
*
|
2005-10-04 |
2009-02-26 |
Nitromed, Inc. |
Methods for treating respiratory disorders
|
US8119358B2
(en)
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
US8026377B2
(en)
|
2005-11-08 |
2011-09-27 |
Ranbaxy Laboratories, Limited |
Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
|
US7838023B2
(en)
*
|
2005-11-16 |
2010-11-23 |
Nitromed, Inc. |
Furoxan compounds, compositions and methods of use
|
TW200735866A
(en)
|
2005-11-18 |
2007-10-01 |
Synta Pharmaceuticals Corp |
Compounds for the treatment of proliferative disorders
|
EP1968584A2
(en)
*
|
2005-12-20 |
2008-09-17 |
Nitromed, Inc. |
Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
|
WO2007075542A2
(en)
*
|
2005-12-22 |
2007-07-05 |
Nitromed, Inc. |
Nitric oxide enhancing pyruvate compounds, compositions and methods of use
|
WO2007087246A2
(en)
|
2006-01-24 |
2007-08-02 |
Merck & Co., Inc. |
Jak2 tyrosine kinase inhibition
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
PT3279663T
(pt)
|
2006-03-15 |
2021-09-24 |
Brigham & Womens Hospital Inc |
Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias
|
CA2647859C
(en)
|
2006-03-29 |
2016-01-05 |
Nitromed, Inc. |
Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
|
PL2010528T3
(pl)
|
2006-04-19 |
2018-03-30 |
Novartis Ag |
6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
|
US20080057590A1
(en)
|
2006-06-07 |
2008-03-06 |
Mickey Urdea |
Markers associated with arteriovascular events and methods of use thereof
|
US8158156B2
(en)
|
2006-06-19 |
2012-04-17 |
Alpharma Pharmaceuticals, Llc |
Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
|
US8128460B2
(en)
*
|
2006-09-14 |
2012-03-06 |
The Material Works, Ltd. |
Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20080208179A1
(en)
*
|
2006-10-26 |
2008-08-28 |
Reliant Technologies, Inc. |
Methods of increasing skin permeability by treatment with electromagnetic radiation
|
JP5280368B2
(ja)
|
2006-10-31 |
2013-09-04 |
バイオ−テック エンバイロメンタル,エルエルシー |
高分子材料を生分解性にする化学添加剤
|
US8513329B2
(en)
|
2006-10-31 |
2013-08-20 |
Bio-Tec Environmental, Llc |
Chemical additives to make polymeric materials biodegradable
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
RS51940B
(en)
|
2006-12-22 |
2012-02-29 |
Recordati Ireland Limited |
Combined TH2δ LIGANAD THERAPY AND NSAID FOR LOWER URINARY TRACT DISORDERS
|
SI2805945T1
(sl)
|
2007-01-10 |
2019-09-30 |
Msd Italia S.R.L. |
Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
|
JP2010516679A
(ja)
*
|
2007-01-19 |
2010-05-20 |
マリンクロット インコーポレイテッド |
診断用および治療用シクロオキシゲナーゼ−2結合リガンド
|
EP2132177B1
(en)
|
2007-03-01 |
2013-07-17 |
Novartis AG |
Pim kinase inhibitors and methods of their use
|
GB0704407D0
(en)
|
2007-03-07 |
2007-04-18 |
Glaxo Group Ltd |
Compounds
|
AU2008242764B2
(en)
|
2007-04-18 |
2013-10-24 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
KR20100017866A
(ko)
|
2007-05-21 |
2010-02-16 |
노파르티스 아게 |
Csf-1r 억제제, 조성물 및 사용 방법
|
CA2690191C
(en)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
BRPI0814542A2
(pt)
|
2007-07-12 |
2014-09-30 |
Tragara Pharmaceuticals Inc |
Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
|
US7943658B2
(en)
*
|
2007-07-23 |
2011-05-17 |
Bristol-Myers Squibb Company |
Indole indane amide compounds useful as CB2 agonists and method
|
US8263641B2
(en)
|
2007-09-10 |
2012-09-11 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
CA2717509A1
(en)
|
2008-03-03 |
2009-09-11 |
Tiger Pharmatech |
Tyrosine kinase inhibitors
|
GB2462022B
(en)
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
TWI392673B
(zh)
|
2008-08-27 |
2013-04-11 |
Calcimedica Inc |
調控細胞內鈣離子濃度之化合物
|
EP2177215A1
(en)
|
2008-10-17 |
2010-04-21 |
Laboratorios Del. Dr. Esteve, S.A. |
Co-crystals of tramadol and NSAIDs
|
CN101429181A
(zh)
*
|
2008-12-18 |
2009-05-13 |
毛近隆 |
对羟基苯丙烯酸衍生物及其应用
|
US20100160351A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
|
WO2010071865A1
(en)
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
EP2405915B1
(en)
|
2009-03-10 |
2018-10-24 |
Euro-Celtique S.A. |
Immediate release pharmaceutical compositions comprising oxycodone and naloxone
|
WO2011012622A1
(en)
|
2009-07-30 |
2011-02-03 |
Glaxo Group Limited |
Benzoxazinone derivatives for the treatment of glytl mediated disorders
|
WO2011023753A1
(en)
|
2009-08-27 |
2011-03-03 |
Glaxo Group Limited |
Benzoxazine derivatives as glycine transport inhibitors
|
WO2011032175A1
(en)
|
2009-09-14 |
2011-03-17 |
Nuon Therapeutics, Inc. |
Combination formulations of tranilast and allopurinol and methods related thereto
|
CA2777043C
(en)
|
2009-10-14 |
2015-12-15 |
Schering Corporation |
Substituted piperidines that increase p53 activity and the uses thereof
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US8586624B2
(en)
|
2009-12-16 |
2013-11-19 |
N30 Pharmaceuticals, Inc. |
Thiophene inhibitors of S-nitrosoglutathione reductase
|
GB201000685D0
(en)
|
2010-01-15 |
2010-03-03 |
Glaxo Group Ltd |
Novel compounds
|
SG182821A1
(en)
|
2010-02-01 |
2012-08-30 |
Hospital For Sick Children |
Remote ischemic conditioning for treatment and prevention of restenosis
|
SG10201502031XA
(en)
|
2010-03-31 |
2015-05-28 |
Hospital For Sick Children |
Use of remote ischemic conditioning to improve outcome after myocardial infarction
|
AU2011248579A1
(en)
|
2010-04-27 |
2012-11-29 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
DK2563776T3
(en)
|
2010-04-27 |
2016-09-19 |
Calcimedica Inc |
Relations that modulate intracellular calcium
|
GB201007789D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
GB201007791D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel compounds
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
US9115132B2
(en)
|
2010-07-09 |
2015-08-25 |
Convergence Pharmaceuticals Limited |
Tetrazole compounds as calcium channel blockers
|
US8518907B2
(en)
|
2010-08-02 |
2013-08-27 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
EP2606134B1
(en)
|
2010-08-17 |
2019-04-10 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
SI3333188T1
(sl)
|
2010-08-19 |
2022-04-29 |
Zoetis Belgium S.A. |
Protitelesa proti NGF in njihova uporaba
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
JP5916149B2
(ja)
|
2010-08-27 |
2016-05-11 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
WO2012036997A1
(en)
|
2010-09-16 |
2012-03-22 |
Schering Corporation |
Fused pyrazole derivatives as novel erk inhibitors
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
MY166034A
(en)
|
2010-12-22 |
2018-05-21 |
Purdue Pharma Lp |
Encased tamper resistant controlled release dosage forms
|
JP5638151B2
(ja)
|
2010-12-23 |
2014-12-10 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
不正加工抵抗性の(tamperresistant)固形経口剤形
|
ES2541416T3
(es)
|
2011-01-19 |
2015-07-20 |
Convergence Pharmaceuticals Limited |
Derivados de piperazina como bloqueadores de los canales de calcio Cav2.2
|
WO2012143879A1
(en)
|
2011-04-21 |
2012-10-26 |
Piramal Healthcare Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
RS61793B1
(sr)
|
2011-05-20 |
2021-06-30 |
H Lundbeck As |
Anti-cgrp kompozicije i njihova upotreba
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
US9221809B2
(en)
|
2011-10-31 |
2015-12-29 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
|
GB201122113D0
(en)
|
2011-12-22 |
2012-02-01 |
Convergence Pharmaceuticals |
Novel compounds
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
US9265772B2
(en)
|
2012-05-11 |
2016-02-23 |
Reset Therapeutics, Inc. |
Carbazole-containing sulfonamides as cryptochrome modulators
|
CA2875783C
(en)
|
2012-06-06 |
2018-12-11 |
Zoetis Llc |
Caninized anti-ngf antibodies and methods thereof
|
AU2013323508B2
(en)
|
2012-09-28 |
2017-11-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are ERK inhibitors
|
WO2014059333A1
(en)
|
2012-10-12 |
2014-04-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
ES2651347T3
(es)
|
2012-11-28 |
2018-01-25 |
Merck Sharp & Dohme Corp. |
Composiciones y métodos para el tratamiento del cáncer
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
US9149533B2
(en)
|
2013-02-05 |
2015-10-06 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
US9725452B2
(en)
|
2013-03-15 |
2017-08-08 |
Presidents And Fellows Of Harvard College |
Substituted indoles and pyrroles as RIP kinase inhibitors
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
TWI634114B
(zh)
*
|
2013-05-08 |
2018-09-01 |
永恒生物科技公司 |
作為激酶抑制劑之呋喃酮化合物
|
EP3019171B1
(en)
|
2013-07-11 |
2018-09-05 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
NZ716267A
(en)
|
2013-07-23 |
2017-05-26 |
Euro Celtique Sa |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US9611263B2
(en)
|
2013-10-08 |
2017-04-04 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US10413520B2
(en)
|
2014-01-29 |
2019-09-17 |
Crystalgenomics, Inc. |
Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability
|
KR101446601B1
(ko)
*
|
2014-01-29 |
2014-10-07 |
크리스탈지노믹스(주) |
5-(4-(아미노설포닐)페닐)-2,2-디메틸-4-(3-플루오로페닐)-3(2h)-퓨라논을 포함하는 약학적 조성물 및 캡슐 제형
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
GB201417497D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417500D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417499D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
RU2563876C1
(ru)
*
|
2014-11-11 |
2015-09-27 |
Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный университет" (СПбГУ) |
Способ получения 2,2-диалкил-4,5-диарилфуран-3(2н)-онов
|
EP3268367B8
(en)
|
2015-03-12 |
2022-11-16 |
Merck Sharp & Dohme LLC |
Carboxamide inhibitors of irak4 activity
|
WO2016144846A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of irak4 activity
|
US10040802B2
(en)
|
2015-03-12 |
2018-08-07 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of IRAK4 activity
|
EP3292213A1
(en)
|
2015-05-04 |
2018-03-14 |
Academisch Medisch Centrum |
Biomarkers for the detection of aspirin insensitivity
|
SG11201808630WA
(en)
|
2016-04-15 |
2018-10-30 |
Alder Biopharmaceuticals Inc |
Humanized anti-pacap antibodies and uses thereof
|
WO2017222575A1
(en)
|
2016-06-23 |
2017-12-28 |
Collegium Pharmaceutical, Inc. |
Process of making more stable abuse-deterrent oral formulations
|
CN109475527A
(zh)
|
2016-07-21 |
2019-03-15 |
荷兰联合利华有限公司 |
用于治疗皮肤损伤的内酰胺
|
CN109475526A
(zh)
|
2016-07-21 |
2019-03-15 |
荷兰联合利华有限公司 |
用于治疗呼吸道感染的内酰胺
|
WO2018015280A1
(en)
|
2016-07-21 |
2018-01-25 |
Unilever Plc |
4-(4-chlorophenyl)-5-methylene-pyrrol-2-one and 5-methylene-4-(p-tolyl)pyrrol-2-one for use in the treatment of gram negative bacterial infections
|
EP3525785A4
(en)
|
2016-10-12 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
KDM5 INHIBITORS
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
RU2020129265A
(ru)
|
2018-03-12 |
2022-04-12 |
ЗОИТИС СЕРВИСЕЗ ЭлЭлСи |
Антитела против ngf и связанные с ними способы
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
CA3113353A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
US20220047518A1
(en)
|
2018-09-19 |
2022-02-17 |
Moderna TX, Inc. |
Peg lipids and uses thereof
|
CA3119728A1
(en)
|
2018-11-21 |
2020-05-28 |
Tremeau Pharmaceuticals, Inc. |
Purified forms of rofecoxib, methods of manufacture and use
|
CN110452198B
(zh)
*
|
2019-09-03 |
2021-03-26 |
山东鲁抗舍里乐药业有限公司 |
一种非罗考昔的制备方法
|
CN110452199B
(zh)
*
|
2019-09-03 |
2021-03-30 |
山东鲁抗舍里乐药业有限公司 |
一种非罗考昔的制备方法
|
US10945992B1
(en)
|
2019-11-13 |
2021-03-16 |
Tremeau Pharmaceuticals, Inc. |
Dosage forms of rofecoxib and related methods
|
WO2021126731A1
(en)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
CN114014824B
(zh)
*
|
2020-12-09 |
2023-06-13 |
上海科技大学 |
一种杂环化合物的应用
|
US20240199571A1
(en)
*
|
2021-03-11 |
2024-06-20 |
Medshine Discovery Inc. |
Thiophene compound and application thereof
|
CA3209491A1
(en)
|
2021-03-15 |
2022-09-22 |
Saul Yedgar |
Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease
|
US11161833B1
(en)
|
2021-04-09 |
2021-11-02 |
Tremeau Pharmaceuticals, Inc. |
Deuterated etoricoxib, methods of manufacture, and use thereof
|
IL310885A
(en)
|
2021-08-27 |
2024-04-01 |
H Lundbeck As |
Treatment of cluster headache using anti-CGRP antibodies
|